All Stories

Anti-aging biotech NewLimit raises $130M to push liver reprogramming med into clinic

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million series B fundraising round.

May 8, 2025 - 23:18
 0
Anti-aging biotech NewLimit raises $130M to push liver reprogramming med into clinic
Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million series B fundraising round.
Read More

Tags:

Previous Article

250 more NIH workers laid off, including cuts at the National Cancer Institute

Next Article

Fierce Biotech Fundraising Tracker '25: Haya hauls in $65M; NewLimit nabs $130M

Related Posts

Tariffs will make financial case for pharma M&A ‘more difficult,’ says Roche CEO

Tariffs will make financial case for pharma M&A ‘more d...

Apr 24, 2025  0

Sequel Med Tech to link Senseonics’ 365-day CGM with upcoming twiist insulin pump

Sequel Med Tech to link Senseonics’ 365-day CGM with up...

Apr 29, 2025  0

Lowering blood pressure reduces dementia risk in patients with hypertension, large China trial reveals

Lowering blood pressure reduces dementia risk in patien...

Apr 24, 2025  0